NurseJet
Back to Discover
Research ArticleResearchMedication Safety

Mitapivat reduced transfusion burden in transfusion-dependent thalassemia

Lancet (PubMed)Sep 12, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a phase 3 randomized trial, adults with transfusion-dependent alpha- or beta-thalassemia were more likely to achieve the prespecified transfusion-reduction response with oral mitapivat than with placebo.

What NurseJet pulled from the source

The response occurred in 52 of 171 participants assigned to mitapivat (30%) and 11 of 87 assigned to placebo (13%), an adjusted difference of 18 percentage points (95% CI 8 to 27) over 48 weeks.

Why this matters for nurses

A reduced transfusion requirement could change treatment burden for adults with transfusion-dependent thalassemia, while the discontinuation difference underscores the need to pair efficacy with medication-tolerance monitoring.

Bedside takeaway

Pair the transfusion-reduction signal with careful medication-tolerance and transfusion tracking.

Key takeaways

  • The international double-blind trial randomized 258 adults in a 2:1 ratio to mitapivat 100 mg twice daily or placebo.
  • Adverse events were reported in 90% of mitapivat-treated participants and 84% of placebo-treated participants.
  • Treatment was discontinued because of adverse events in 6% of participants who received mitapivat and 1% who received placebo; no deaths were reported.

Practice implications

  • Track ordered transfusions, treatment tolerance, and reported symptoms accurately for patients receiving mitapivat, and escalate adverse effects through the hematology medication pathway.

Limitations & cautions

  • Abstract-only summary. The trial lasted 48 weeks, enrolled adults only, was funded by the drug manufacturer, and the abstract does not report longer-term outcomes.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Lancet (PubMed)

Lancet (PubMed). Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42721980/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Family Medicine and Community Health (PubMed)

A dose-response meta-analysis of prospective cohorts found that higher ultra-processed food intake was associated with higher risks of cardiovascular events, cancer, obesity or overweight, metabolic syndrome or diabetes, depression or anxiety, digestive disease, and all-cause mortality.

Med-SurgTelemetryAI summaryReview source

Journal of Clinical Nursing (PubMed)

A mixed-methods systematic review found that nurses viewed situational awareness, teamwork, communication, leadership, experience, intuition, and freedom from retribution as important to recognizing and escalating clinical deterioration.

LeadershipMed-SurgAI summaryReview source

Journal of Advanced Nursing (PubMed)

A systematic review and meta-analysis found moderate-certainty evidence that nurse-led or nurse-coordinated multicomponent nonpharmacologic programs reduced delirium incidence in hospitalized adults aged 60 or older.

GeriatricsMed-SurgAI summaryReview source